Drug metabolism and personalized therapy · 2026
Assessment of the impact of valproic acid co-administration on clozapine plasma concentrations in Tunisian patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ben Hammamia Syrine, Souissi Safa, Bettoumia Mariem, Ben Sassi Mouna, Ferchichi Khouloud, Daldoul Mouna, El Jebari Hanene, Zouari Mohamed, Salouage Issam, Charfi Rim, Daghfous Riadh, Gaies Emna, Trabelsi Sameh
Аннотация
OBJECTIVES: Reports on drug-drug interactions between Valproic Acid (VPA) and Clozapine (CLZ) are very inconsistent. Previous reports demonstrate that VPA may exhibit either inhibitory or inductive effects or have no effect on CLZ pharmacokinetics. The aim of this study was to investigate the impact of VPA on plasma CLZ concentrations in a series of Tunisian patients.
METHODS: This retrospective study was conducted from 2010 to 2025 at the Clinical Pharmacology Department of the Tunisian National Pharmacovigilance Center and included samples of patients treated by CLZ for schizophrenia.
RESULTS: A total of 1,035 samples were analyzed: 814 corresponded to CLZ monotherapy and 221 to combined of VPA and CLZ therapy. The median CLZ plasma concentration-to-dose ratio (C/D ratio) was significantly higher in the monotherapy group than in the combination group (0.87 vs. 0.75 ng/mL per mg/day; p<0.05). Within the combination group, the CLZ C/D ratio was significantly lower in men than in women (0.67 vs. 1.16 ng/mL per mg/day; p<0.05).
CONCLUSIONS: Our study demonstrates a significant inductive effect of VPA on CLZ metabolism, which may be influenced by factors such as gender. Hence, clinicians should be aware of the critical need for CLZ monitoring in clinical practice to personalize treatment adjustment.
METHODS: This retrospective study was conducted from 2010 to 2025 at the Clinical Pharmacology Department of the Tunisian National Pharmacovigilance Center and included samples of patients treated by CLZ for schizophrenia.
RESULTS: A total of 1,035 samples were analyzed: 814 corresponded to CLZ monotherapy and 221 to combined of VPA and CLZ therapy. The median CLZ plasma concentration-to-dose ratio (C/D ratio) was significantly higher in the monotherapy group than in the combination group (0.87 vs. 0.75 ng/mL per mg/day; p<0.05). Within the combination group, the CLZ C/D ratio was significantly lower in men than in women (0.67 vs. 1.16 ng/mL per mg/day; p<0.05).
CONCLUSIONS: Our study demonstrates a significant inductive effect of VPA on CLZ metabolism, which may be influenced by factors such as gender. Hence, clinicians should be aware of the critical need for CLZ monitoring in clinical practice to personalize treatment adjustment.